Sensorion planned to launch 2 clinical trials in 2016.
Dysfunction or complete loss of function of the vestibular or cochlear system can induce vertigo, imbalance, tinnitus, hearing loss and leads to transient or permanent disability. Unfortunately there are no truly effective, approved and well tolerated treatments available for patients suffering from inner ear pathologies.
Founded in 2009, Sensorion is a French biopharmaceutical company dedicated to the development of targeted and innovative therapies to treat such disorders and fill the currently unmet medical needs.
The company is located in Montpellier (France). At the interface between academic research and industrial development, we adopt a multidisciplinary approach in collaboration with various partners in the ENT field (researchers, clinicians…) to develop new drugs.